These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19945692)

  • 1. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
    Ghazi M; Roux C
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
    Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
    Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
    Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
    Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
    Aapro M
    Breast; 2006 Feb; 15 Suppl 1():S30-40. PubMed ID: 16500238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.